Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Kentarou Kudou
Observed names:
K. K. Kudou,
K. Kudou,
Kentaro Kudo,
Kentaro Kudou,
Kudou, Kentarou,
工藤健太郎
show all 6
Institution:
Takeda (Japan)
Observed institutions:
Rakuwakai Otowa Hospital,
Osaka Rosai Hospital,
Takeda (Japan),
Kobe University,
The University of Tokyo,
Nippon Medical School,
Kindai University
show all 7
ORCID:
0000-0003-0125-6174
Observed ORCID:
0000-0003-0125-6174
OpenAlex ID:
A5076398769
Randomised clinical trial: vonoprazan, a novel potassium‐competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis
2015
·
K. Ashida
, Y. Sakurai
, et al.
·
Alimentary Pharmacology & Therapeutics
·
327
PDF
Randomised clinical trial: a dose‐ranging study of vonoprazan, a novel potassium‐competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis
2015
·
K. Ashida
, Y. Sakurai
, et al.
·
Alimentary Pharmacology & Therapeutics
·
204
PDF
Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole
2018
·
Kiyoshi Ashida
, Katsuhiko Iwakiri
, et al.
·
World Journal of Gastroenterology
·
119
PDF
Oral Gonadotropin-Releasing Hormone Antagonist Relugolix Compared With Leuprorelin Injections for Uterine Leiomyomas: A Randomized Controlled Trial
2019
·
Yutaka Osuga
, Kazuaki Enya
, et al.
·
Obstetrics and Gynecology
·
111
PDF
Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain in a dose–response manner: a randomized, double-blind, placebo-controlled study
2020
·
Yutaka Osuga
, Yoshifumi Seki
, et al.
·
Fertility and Sterility
·
105
Relugolix, a novel oral gonadotropin-releasing hormone antagonist, in the treatment of pain symptoms associated with uterine fibroids: a randomized, placebo-controlled, phase 3 study in Japanese women
2019
·
Yutaka Osuga
, Kazuaki Enya
, et al.
·
Fertility and Sterility
·
86
PDF
Evaluation of the Efficacy and Safety of Vonoprazan in Patients with Nonerosive Gastroesophageal Reflux Disease: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study
2016
·
Yoshikazu Kinoshita
, Yuuichi Sakurai
, et al.
·
Current Therapeutic Research
·
76
PDF
Brigatinib in Japanese Patients With ALK-Positive NSCLC Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial
2020
·
Makoto Nishio
, Tatsuya Yoshida
, et al.
·
Journal of Thoracic Oncology
·
74
A randomized, double-blind study to evaluate the acid-inhibitory effect of vonoprazan (20 mg and 40 mg) in patients with proton-pump inhibitor-resistant erosive esophagitis
2017
·
Katsuhiko Iwakiri
, Yuuichi Sakurai
, et al.
·
Therapeutic Advances in Gastroenterology
·
70
PDF
Vonoprazan non‐inferior to lansoprazole in treating duodenal ulcer and eradicating Helicobacter pylori in Asian patients
2022
·
Xiaohua Hou
, Fandong Meng
, et al.
·
Journal of Gastroenterology and Hepatology
·
61
Efficacy and Safety of Vonoprazan in Patients With Nonerosive Gastroesophageal Reflux Disease: A Randomized, Placebo-Controlled, Phase 3 Study
2019
·
Yoshikazu Kinoshita
, Yuuichi Sakurai
, et al.
·
Clinical and Translational Gastroenterology
·
57
Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in women with endometriosis-associated pain: phase 2 safety and efficacy 24-week results
2021
·
Yutaka Osuga
, Yoshifumi Seki
, et al.
·
BMC Women s Health
·
49
PDF
Efficacy and safety of TAK-085 compared with eicosapentaenoic acid in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: The omega-3 fatty acids randomized double-blind (ORD) study
2013
·
Ichiro Tatsuno
, Yasushi Saito
, et al.
·
Journal of clinical lipidology
·
47
Relugolix for oral treatment of uterine leiomyomas: a dose-finding, randomized, controlled trial
2021
·
Hiroshi Hoshiai
, Yoshifumi Seki
, et al.
·
BMC Women s Health
·
34
PDF
Long-term safety and efficacy of TAK-085 in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: The omega-3 fatty acids randomized long-term (ORL) study
2013
·
Ichiro Tatsuno
, Yasushi Saito
, et al.
·
Journal of clinical lipidology
·
34
Efficacy and safety of leuprorelin acetate 6-month depot in prostate cancer patients: a Phase III, randomized, open-label, parallel-group, comparative study in Japan
2015
·
Kazuhiro Suzuki
, Mikio Namiki
, et al.
·
Japanese Journal of Clinical Oncology
·
21
PDF
Brigatinib in Japanese patients with ALK ‐positive non‐small‐cell lung cancer: Final results of the phase 2 J‐ALTA trial
2023
·
Tatsuya Yoshida
, Toru Kumagai
, et al.
·
Cancer Science
·
16
PDF
Efficacy and Safety of Vonoprazan-Based Quadruple Therapy for the Eradication of Helicobacter pylori in Patients with Peptic Ulcers: A Pooled Analysis of Two Randomized, Double-Blind, Double-Dummy, Phase 3 Trials
2024
·
Xiaohua Hou
, Jiangbin Wang
, et al.
·
Biological and Pharmaceutical Bulletin
·
15
PDF
Phase 2 Study of Relugolix vs Placebo in Heavy Menstrual Bleeding Associated With Uterine Fibroids [17H]
2017
·
Hiroshi Hoshiai
, Yoshifumi Seki
, et al.
·
Obstetrics and Gynecology
·
12
Effect of TAK ‐085 on Low‐density Lipoprotein Particle Size in Patients with Hypertriglyceridemia: A Double‐blind Randomized Clinical Study
2015
·
Ichiro Tatsuno
, Kentarou Kudou
, et al.
·
Cardiovascular Therapeutics
·
9
PDF
Tu1052 A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of TAK-438 (10 mg or 20 mg Once-Daily) Compared to Lansoprazole (15 mg Once-Daily) in a 24-Week Maintenance Treatment for Healed Erosive Esophagitis
2014
·
Eiji Umegaki
, Katsuhiko Iwakiri
, et al.
·
Gastroenterology
·
9
Efficacy and safety of brigatinib in patients with ALK TKI-naive advanced ALK+ NSCLC: Integrated analysis of the ALTA-1L and J-ALTA trials
2025
·
D. Ross Camidge
, Shunichi Sugawara
, et al.
·
Lung Cancer
·
8
PDF
Oral Gonadotropin-Releasing Hormone Antagonist Relugolix Compared With Leuprorelin Injections for Uterine Leiomyomas: A Randomized Controlled Trial
2019
·
Yutaka Osuga
, Kazuaki Enya
, et al.
·
Obstetrical & Gynecological Survey
·
8
Tu1059 A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of TAK-438 (20 mg Once-Daily) Compared to Lansoprazole (30 mg Once-Daily) in Patients With Erosive Esophagitis
2014
·
Katsuhiko Iwakiri
, Eiji Umegaki
, et al.
·
Gastroenterology
·
8
PDF
Brigatinib in Japanese patients with tyrosine kinase inhibitor-naive ALK-positive non-small cell lung cancer: first results from the phase 2 J-ALTA study
2022
·
Shunichi Sugawara
, Masashi Kondo
, et al.
·
International Journal of Clinical Oncology
·
6
PDF
Show more works
View as search
Works count:
50
Citation count:
1,587
H-index:
16
I10-index:
19
Year
Topic
Type